Home Cart Sign in  
Chemical Structure| 934343-74-5 Chemical Structure| 934343-74-5

Structure of NVP-HSP990
CAS No.: 934343-74-5

Chemical Structure| 934343-74-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NVP-HSP990 is a potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Synonyms: HSP990; NVP-HSP990; HSP-990

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NVP-HSP990

CAS No. :934343-74-5
Formula : C20H18FN5O2
M.W : 379.39
SMILES Code : O=C1N[C@@H](C2=CC=C(F)C=C2C3=NC(OC)=CC=C3)CC4=NC(N)=NC(C)=C41
Synonyms :
HSP990; NVP-HSP990; HSP-990
MDL No. :MFCD22628859
InChI Key :WSMQUUGTQYPVPD-OAHLLOKOSA-N
Pubchem ID :46216556

Safety of NVP-HSP990

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of NVP-HSP990

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary cultured astrocytes 8 nM 24 hours Evaluate the effect of HSP990 on EAAT2 protein levels, results showed HSP990 significantly upregulated EAAT2 protein levels at 8 nM concentration Theranostics. 2020 Jul 9;10(18):8415-8429
MIA PaCa-2 pancreatic carcinoma cells 0.01, 0.02, 0.05, 0.1 µM 24 hours To evaluate the effect of NVP-HSP990 on clonogenic survival of MIA PaCa-2 cells, showing significant reduction in colony numbers at 0.05 and 0.1 μM. Radiat Oncol. 2013 Feb 28;8:42
U251 glioblastoma cells 0.01, 0.02, 0.05, 0.1 µM 24 hours To evaluate the effect of NVP-HSP990 on clonogenic survival of U251 cells, showing significant reduction in colony numbers at 0.05 and 0.1 μM. Radiat Oncol. 2013 Feb 28;8:42
Human bronchopulmonary neuroendocrine NCI-H727 tumor cells 0.1-100 nM 24, 72, 144 hours To assess the effect of HSP990 on NCI-H727 cell viability. Results showed that HSP990 significantly suppressed cell viability, with the lowest effective concentration at 10 nM. Int J Oncol. 2013 Dec;43(6):1824-32
Human pancreatic neuroendocrine BON1 tumor cells 0.1-100 nM 24, 72, 144 hours To assess the effect of HSP990 on BON1 cell viability. Results showed that HSP990 significantly suppressed cell viability, with the lowest effective concentration at 5 nM, and maximum inhibition of 97% after 144 h. Int J Oncol. 2013 Dec;43(6):1824-32
HT29 cells 0-2 µM 48 hours To evaluate the effects of NVP-HSP990 on apoptosis, necrosis, and cellular biochemical activity in HT29 cells. Results showed that NVP-HSP990 at 125 nM significantly increased caspase-3 levels, indicating induction of apoptosis. MTS assay showed a significant decrease in cell survival. Cell Stress Chaperones. 2017 Mar;22(2):293-306
OVCAR3CisR 25.0 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on cisplatin-resistant OVCAR3CisR ovarian cancer cell lines, showing an IC50 of 25.0 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
OVCAR3 27.6 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on OVCAR3 ovarian cancer cell lines, showing an IC50 of 27.6 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
CaOV3CisR 55.6 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on cisplatin-resistant CaOV3CisR ovarian cancer cell lines, showing an IC50 of 55.6 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
CaOV3 40.9 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on CaOV3 ovarian cancer cell lines, showing an IC50 of 40.9 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
A2780CisR 29.8 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on cisplatin-resistant ovarian cancer cell lines, showing an IC50 of 29.8 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
A2780 20.1 nM (IC50) 72 hours To evaluate the cytotoxic effect of HSP990 on ovarian cancer cell lines, showing an IC50 of 20.1 nM. Int J Mol Sci. 2020 Nov 5;21(21):8300.
Human midgut carcinoid GOT1 cells 0.1-100 nM 72, 144 hours To assess the effect of HSP990 on GOT1 cell viability. Results showed that HSP990 significantly suppressed cell viability, with the lowest effective concentration at 5 nM. Int J Oncol. 2013 Dec;43(6):1824-32

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Temporal lobe epilepsy model Oral gavage 0.1 mg/kg Once every other day for several weeks Evaluate the antiepileptic effect of HSP990, results showed 0.1 mg/kg HSP990 significantly upregulated EAAT2 levels and inhibited spontaneous seizures Theranostics. 2020 Jul 9;10(18):8415-8429
Transgenic P23H-1 rats P23H opsin mutation-induced retinal degeneration model Oral gavage 1 mg/kg (female) or 5 mg/kg (male) Single dose To investigate the protective effect of HSP990 on retinal degeneration caused by P23H opsin mutation, results showed that HSP990 enhanced visual function and delayed photoreceptor degeneration. Hum Mol Genet. 2014 Apr 15;23(8):2164-75
Mice ZQ175 knock-in mouse model Oral gavage 12 mg/kg Single dose, tissues collected 4 hours post-dosing To evaluate the effect of NVP-HSP990 in inducing the heat shock response in zQ175 mice, finding that the heat shock response becomes impaired with disease progression and is not caused by a reduction in HSF1 levels. Sci Rep. 2021 Apr 27;11(1):9117
Mice Wild-type mice Oral 12 mg/kg Single dose To investigate the effect of ageing on HSF1 activity and heat shock protein expression in different brain regions and peripheral tissues. Results showed reduced induction of HSP70 and HSP25 in the hearts of old mice, but no age-related decline in the HSR was observed in other tissues. Hum Mol Genet. 2014 Jul 15;23(14):3641-56

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.18mL

2.64mL

1.32mL

26.36mL

5.27mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories